We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » B.Braun Gets 483 for Poor Inquiries into Batch Problems

B.Braun Gets 483 for Poor Inquiries into Batch Problems

September 24, 2014

The FDA found B.Braun’s investigations into leaky products to be lacking in detail, handing the drugmaker a Form 483.

During a January to February inspection of the drugmaker’s Irvine, Calif., facility, the FDA was troubled by leaking presterile bioburden samples taken from three batches during August 2013. B.Braun investigated the issue but failed to review batch records and maintenance work orders for certain equipment.

The investigations stated that the presterile bioburden result met specification and the company concluded that there was no impact on the product. The batches were later released.

Another investigation into batches that failed assay and potency tests was inadequate. While the batches were rejected in January, the drugmaker didn’t determine the root cause and whether other batches could be impacted.

The FDA also chided B.Braun over various quality procedures.

The agency found B.Braun doesn’t perform an adequate 100 percent visual inspection for the detection of particulates in the 250 ml, 500 ml and 1 liter intravenous solutions in Excel brand bags. 

The company says it is working closely with the FDA to address the issues in the form and is “taking the appropriate actions to resolve any identified observations.”

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

  • MedTrace Receives U.S. Patent for Heart Modeling Method

  • NICE Recommends Epidyolex for Tuberous Sclerosis Complex Seizures

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing